Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Alaunos Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Alaunos Therapeutics, Inc.

TCRT

Alaunos Therapeutics, Inc.

About Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc. is a preclinical-stage biopharmaceutical company focused on developing small molecule oral drugs to treat obesity and metabolic disorders. Its lead candidate, ALN1001, aims to offer a differentiated profile by avoiding hormonal manipulation common in current treatments. The company leverages outsourced manufacturing and proprietary research to address unmet needs in weight management, targeting global markets with scalable, non-invasive therapeutic solutions.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Alaunos Therapeutics, Inc.

1
1
Alaunos Therapeutics, Inc. Alaunos Therapeutics Reports Q1 2026 Financial Results with $1.0 Million Net Loss

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
Alaunos Therapeutics, Inc. Alaunos Therapeutics Reports $4.2 Million Net Loss and Strategic Shift to Obesity Program

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Alaunos Therapeutics, Inc. Alaunos Therapeutics Reports Q3 2025 Financial Results with $1.16 Million Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Alaunos Therapeutics, Inc. Alaunos Therapeutics Reports Q2 2025 Financial Results, Shifts Focus to Obesity Therapeutics

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Alaunos Therapeutics, Inc. Alaunos Therapeutics Reports Modest Revenue Increase and Decreased Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Alaunos Therapeutics, Inc. Alaunos Therapeutics Reports $4.7 Million Net Loss for Fiscal Year 2024, Focuses on Obesity Program

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Alaunos Therapeutics, Inc. Alaunos Therapeutics Reports Significant Financial Improvements, Anticipates Cash Runway Extension

Via official filing (AI summary) | over 1 year ago | 0 comments